Beta Blocker for Chronic Wound Healing
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00368602|
Recruitment Status : Terminated (Lack of funding.)
First Posted : August 25, 2006
Last Update Posted : April 7, 2015
|Condition or disease||Intervention/treatment||Phase|
|Ulcer Burns||Drug: Timoptic Other: Placebo||Phase 2|
The purpose of this study is to learn more about how to heal venous leg ulcers faster and to test the safety of a drug and see what effects it has on a venous leg ulcer.
- be interviewed and examined
- have a physical exam
- have blood and urine tested
- have photographs taken of the wound
- apply medication to the leg ulcer as directed
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Beta Adrenergic Receptor Modulation of Burn Wound Healing|
|Study Start Date :||June 2005|
|Actual Primary Completion Date :||June 2007|
|Actual Study Completion Date :||June 2007|
This group receives topical beta adrenergic antagonists (Timoptic) plus standard of care.
Timoptic to be applied to the target wound daily for up to 12 weeks.
Other Name: beta adrenergic antagonists
Placebo Comparator: 2
The group will be given standard of care with placebo medication.
Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.
- The primary efficacy parameter will be complete ulcer healing, which is defined as 100% epithelialization with no drainage or need for an absorptive dressing. [ Time Frame: 12 weeks ]
- 100% re-epithelialization will be clinically determined at each visit by the Investigator. [ Time Frame: 12 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00368602
|United States, California|
|VA Medical Center|
|Mather, California, United States, 95655|
|Principal Investigator:||Rivkah R Isseroff, MD||University of California, Davis|